Ovarian cancer is hard to treat, with high rates of recurrence and resistance to standard therapies like platinum-based chemotherapy. A new immunotherapy, PHST001, developed by Pheast Therapeutics, offers hope. It is a macrophage checkpoint inhibitor and has received Fast Track designation from the FDA for advanced ovarian cancer.
Unlike most immunotherapies that target T cells, PHST001 focuses on macrophages, immune cells that can “eat” cancer cells. Tumors use a protein called CD24 to avoid being destroyed. PHST001 blocks this “don’t eat me” signal, allowing macrophages to recognize and attack the cancer.
PHST001 is in a Phase 1 trial for patients with advanced or resistant solid tumors, including ovarian cancer. The FDA’s Fast Track designation speeds up development and review for:
Monotherapy in advanced platinum-resistant ovarian cancer.
Combination with chemotherapy in platinum-sensitive ovarian cancer.
Preclinical studies show PHST001 helps macrophages engulf cancer cells and shrink tumors in animal models. If clinical trials confirm safety and effectiveness, PHST001 could become a new treatment option for patients resistant to standard therapies, offering fresh hope in the fight against ovarian cancer.